Current treatment status-Not currently treated Posts on Medivizor
Navigation Menu

Current treatment status-Not currently treated Posts on Medivizor

Evaluating the effectiveness and safety outcomes of pembrolizumab plus GVD chemotherapy combination in patients with relapsed or refractory classical Hodgkin lymphoma.

Evaluating the effectiveness and safety outcomes of pembrolizumab plus GVD chemotherapy combination in patients with relapsed or refractory classical Hodgkin lymphoma.

Posted by on Aug 22, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of pembrolizumab (Keytruda) plus GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) as second-line therapy for patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The data showed that the pembrolizumab plus GVD combination is safe and highly effective...

Read More

Adding isatuximab to carfilzomib and dexamethasone therapy for the treatment of relapsed multiple myeloma.

Adding isatuximab to carfilzomib and dexamethasone therapy for the treatment of relapsed multiple myeloma.

Posted by on Aug 22, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding isatuximab (Sarclisa) to carfilzomib (Kyprolis) and dexamethasone (Decadron) combination (Kd) for patients with previously treated relapsed multiple myeloma (MM). The data showed that adding isatuximab to the Kd regimen reduced the risk of disease progression or death for these...

Read More

Is surgery of metastases effective after failure of modern whole-body treatments in patients with advanced melanoma?

Is surgery of metastases effective after failure of modern whole-body treatments in patients with advanced melanoma?

Posted by on Aug 22, 2021 in Melanoma | 0 comments

In a nutshell This study looked at the use of surgery for spread disease (metastases) in patients with advanced melanoma when other whole-body treatments had failed. It found that surgical removal of metastases improved the outcomes of these patients. Some background Advanced melanoma can spread to many places in the body. It is usually...

Read More

Can a combination of brentuximab vedotin and salvage chemotherapy treat classical Hodgkin’s lymphoma not responding to standard treatment?

Can a combination of brentuximab vedotin and salvage chemotherapy treat classical Hodgkin’s lymphoma not responding to standard treatment?

Posted by on Aug 15, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at the combination of brentuximab vedotin (BV; Adcetris) and ICE salvage chemotherapy with ifosfamide (Ifex), carboplatin (Paraplatin), and etoposide (Etopophos) for the treatment of relapsing or refractory Hodgkin lymphoma (HL). This study showed that BV-ICE was a good salvage treatment option for...

Read More

Searching for patients with unresponsive small cell lung cancer to trial an experimental treatment.

Searching for patients with unresponsive small cell lung cancer to trial an experimental treatment.

Posted by on Aug 15, 2021 in Lung cancer | 0 comments

In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including small cell lung cancer, that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment. This trial is...

Read More

Searching for patients with unresponsive multiple myeloma to trial an experimental treatment.

Searching for patients with unresponsive multiple myeloma to trial an experimental treatment.

Posted by on Aug 15, 2021 in Multiple Myeloma | 0 comments

In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including multiple myeloma (MM), that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment. This trial is...

Read More

Searching for patients with unresponsive B-cell lymphoma to trial an experimental treatment.

Searching for patients with unresponsive B-cell lymphoma to trial an experimental treatment.

Posted by on Aug 15, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including non-Hodgkin lymphoma (NHL), that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment. This trial...

Read More

Searching for patients with unresponsive breast cancer to trial an experimental treatment.

Searching for patients with unresponsive breast cancer to trial an experimental treatment.

Posted by on Aug 15, 2021 in Breast cancer | 0 comments

In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including breast cancer, that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment....

Read More

Evaluating the long-term outcomes of ixazomib in combination with Rd for patients with relapsed or refractory multiple myeloma

Evaluating the long-term outcomes of ixazomib in combination with Rd for patients with relapsed or refractory multiple myeloma

Posted by on Aug 8, 2021 in Multiple Myeloma | 0 comments

In a nutshell This trial looked at the long-term effectiveness and safety of ixazomib (Ixa; Ninlaro) in combination with lenalidomide (R; Revlimid), and dexamethasone (d; Decadron) for the treatment of relapsed/refractory (RR) multiple myeloma (MM). The authors found that there was an improved survival with Ixa-Rd...

Read More

Can idelalisib interruption and dose reduction improve clinical outcomes in patients with relapsed/refractory B-cell lymphoma/leukemia?

Can idelalisib interruption and dose reduction improve clinical outcomes in patients with relapsed/refractory B-cell lymphoma/leukemia?

Posted by on Jul 31, 2021 in Leukemia | 0 comments

In a nutshell This study evaluated the impact of idelalisib (Zydelig) interruption or dose reductions on clinical outcomes in patients with relapsed/refractory (r/r) indolent (painless) non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). This study showed that stopping idelalisib and reducing the dose due to side effects was...

Read More

Can idelalisib interruption and dose reduction improve clinical outcomes in patients with relapsed/refractory B-cell lymphoma?

Can idelalisib interruption and dose reduction improve clinical outcomes in patients with relapsed/refractory B-cell lymphoma?

Posted by on Jul 31, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the impact of idelalisib (Zydelig) interruption or dose reductions on clinical outcomes in patients with relapsed/refractory (r/r) indolent (painless) non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL). This study showed that stopping idelalisib and reducing the dose due to side effects was associated...

Read More

Adding daratumumab to pomalidomide and dexamethasone therapy for treatment of relapsed/refractory multiple myeloma.

Adding daratumumab to pomalidomide and dexamethasone therapy for treatment of relapsed/refractory multiple myeloma.

Posted by on Jul 17, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding daratumumab (Darzalex) to pomalidomide (Pomalyst) and dexamethasone (Decadron) therapy for patients with previously treated relapsed or refractory (r/r) multiple myeloma (MM). The data showed that adding daratumumab to pomalidomide and dexamethasone regimen reduced the risk of...

Read More